3,4-メチレンジオキシアンフェタミン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "3,4-メチレンジオキシアンフェタミン" in Japanese language version.

refsWebsite

Global rank Japanese rank

32nih.gov

4^th place

24^th place

19doi.org

2^nd place

6^th place

5worldcat.org

5^th place

19^th place

3books.google.com

3^rd place

61^st place

2zenodo.org

621^st place

4,635^th place

1ecstasydata.org

low place

1idpc.net

low place

1clinchem.org

low place

1archive.is

87^th place

39^th place

1psychedelicresearch.org

low place

1youtube.com

9^th place

8^th place

1comlaw.gov.au

low place

archive.is

“The First MDA trip and the measurement of 'mystical experience' after MDA, LSD, and Psilocybin”. Psychedelic research (July 18, 2008). July 13, 2012時点のオリジナルよりアーカイブ。2020年12月7日閲覧。

books.google.com

Giuseppe Di Giovanni; Vincenzo Di Matteo; Ennio Esposito (2008). Serotonin-dopamine Interaction: Experimental Evidence and Therapeutic Relevance. Elsevier. pp. 294-. ISBN 978-0-444-53235-0
Shulgin, Alexander; Manning, Tania; Daley, Paul (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds (1st ed.). Berkeley, CA: Transform Press. p. 165. ISBN 9780963009630
Shulgin, Alexander; Shulgin, Ann (1991). PiHKAL: A Chemical Love Story. Lafayette, CA: Transform Press. ISBN 9780963009609

clinchem.org

“Disposition of MDMA and metabolites in human sweat following controlled MDMA administration”. Clinical Chemistry 55 (3): 454-62. (2009). doi:10.1373/clinchem.2008.117093. PMC 2669283. PMID 19168553.

comlaw.gov.au

Poisons Standard (October 2015) comlaw.gov.au

doi.org

de la Torre, R; Farre, M; Roset, Pn; Pizzaro, N; Abanades, S; Segura, M; Segura, M; Cami, J (2004). “Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.”. Therapeutic Drug Monitoring 26 (2): 137-144. doi:10.1097/00007691-200404000-00009. PMID 15228154.
Crean, R. D.; Davis, S. A.; Von Huben, S. N.; Lay, C. C.; Katner, S. N.; Taffe, M. A. (2006-10-13). “Effects of (±)3,4-methylenedioxymethamphetamine, (±)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques”. Neuroscience 142 (2): 515-525. doi:10.1016/j.neuroscience.2006.06.033. PMC 1853374. PMID 16876329.
“Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine”. Journal of Medicinal Chemistry 36 (23): 3700-3706. (1993). doi:10.1021/jm00075a027. PMID 8246240.
Baggott, MJ; Siegrist, JD; Galloway, GP; Robertson, LC; Coyle, JR; Mendelson, JE (2010). “Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxeamphetamine (MDA): A Randomized Controlled Trial in Humans”. PLOS ONE 5 (12): e14074. doi:10.1371/journal.pone.0014074. PMC 2996283. PMID 21152030.
Herndon, Joseph M.; Cholanians, Aram B.; Lau, Serrine S.; Monks, Terrence J. (March 2014). “Glial Cell Response to 3,4-(±)-Methylenedioxymethamphetamine and Its Metabolites”. Toxicological Sciences 138 (1): 130-138. doi:10.1093/toxsci/kft275. ISSN 1096-6080. PMC 3930364. PMID 24299738.
“Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class”. Bioorg. Med. Chem. 19 (23): 7044-8. (December 2011). doi:10.1016/j.bmc.2011.10.007. PMC 3236098. PMID 22037049.
“Therapeutic potential of monoamine transporter substrates”. Curr Top Med Chem 6 (17): 1845-59. (2006). doi:10.2174/156802606778249766. PMID 17017961.
Rothman, Richard B; Baumann, Michael H (2009). “Serotonergic drugs and valvular heart disease”. Expert Opinion on Drug Safety 8 (3): 317-329. doi:10.1517/14740330902931524. ISSN 1474-0338. PMC 2695569. PMID 19505264.
“Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors”. Neurosci. Lett. 177 (1-2): 111-5. (1994). doi:10.1016/0304-3940(94)90057-4. PMID 7824160.
Manzoni, Olivier Jacques; Ray, Thomas S. (2010). “Psychedelics and the Human Receptorome”. PLoS ONE 5 (2): e9019. doi:10.1371/journal.pone.0009019. ISSN 1932-6203. PMC 2814854. PMID 20126400.
Mannich, C.; Jacobsohn, W.; Mannich, Hr. C. (1910). “Uber Oxyphenyl-alkylamine und Dioxyphenyl-alkylamine”. Berichte der Deutschen Chemischen Gesellschaft 41 (1): 189-197. doi:10.1002/cber.19100430126. https://zenodo.org/record/1426387.
Ho, Beng-Thong; McIsaac, William M.; An, Rong; Tansey, L. Wayne; Walker, Kenneth E.; Englert Jr., Leo F.; Noel, Michael B. (1970). “Analogs of a-methylphenethylamine”. Journal of Medicinal Chemistry 13 (1): 26-30. doi:10.1021/jm00295a007. PMID 5412110.
Butterick, John R.; Unrau, A. M. (1974). “Reduction of β-nitrostyrene with sodium bis-(2-methoxyethoxy)-aluminium dihydride. A convenient route to substituted phenylisopropylamines”. Journal of the Chemical Society, Chemical Communications 8 (8): 307-308. doi:10.1039/C39740000307.
大下敏隆、安藤皓章「幻覚作用発現物質であるフェネチルアミン誘導体の合成」『衛生化学』第38巻第6号、日本薬学会、1992年、571-580頁、20 June 2014閲覧。
Elks, J.; Hey, D. H. (1943). “7. β-3 : 4-Methylenedioxyphenylisopropylamine”. J. Chem. Soc. 0: 15-16. doi:10.1039/JR9430000015. ISSN 0368-1769.
“Disposition of MDMA and metabolites in human sweat following controlled MDMA administration”. Clinical Chemistry 55 (3): 454-62. (2009). doi:10.1373/clinchem.2008.117093. PMC 2669283. PMID 19168553.
Naranjo, C.; Shulgin, A. T.; Sargent, T. (1967). “Evaluation of 3, 4-methylenedioxeamphetamine (MDA) as an adjunct to psychotherapy”. Pharmacology 17 (4): 359-364. doi:10.1159/000137100.
Yensen, R.; Di Leo, F. B.; Rhead, J. C.; Richards, W. A.; Soskin, R. A.; Turek, B.; Kurland, A. A. (1976). “MDA-assisted psychotherapy with neurotic outpatients: a pilot study”. The Journal of Nervous and Mental Disease 163 (4): 233-245. doi:10.1097/00005053-197610000-00002. PMID 972325.
“Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers”. Journal of Psychoactive Drugs 51 (2): 108–117. (2019-03-15). doi:10.1080/02791072.2019.1593560. PMID 30967099.

ecstasydata.org

EcstasyData.org. “EcstasyData.org: Test Result Statistics: Substances by Year”. www.ecstasydata.org. 2017年6月27日閲覧。

idpc.net

“Trans European Drug Information” (英語). idpc.net. 2017年6月27日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

de la Torre, R; Farre, M; Roset, Pn; Pizzaro, N; Abanades, S; Segura, M; Segura, M; Cami, J (2004). “Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.”. Therapeutic Drug Monitoring 26 (2): 137-144. doi:10.1097/00007691-200404000-00009. PMID 15228154.
Crean, R. D.; Davis, S. A.; Von Huben, S. N.; Lay, C. C.; Katner, S. N.; Taffe, M. A. (2006-10-13). “Effects of (±)3,4-methylenedioxymethamphetamine, (±)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques”. Neuroscience 142 (2): 515-525. doi:10.1016/j.neuroscience.2006.06.033. PMC 1853374. PMID 16876329.
“Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine”. Journal of Medicinal Chemistry 36 (23): 3700-3706. (1993). doi:10.1021/jm00075a027. PMID 8246240.
Baggott, MJ; Siegrist, JD; Galloway, GP; Robertson, LC; Coyle, JR; Mendelson, JE (2010). “Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxeamphetamine (MDA): A Randomized Controlled Trial in Humans”. PLOS ONE 5 (12): e14074. doi:10.1371/journal.pone.0014074. PMC 2996283. PMID 21152030.
Herndon, Joseph M.; Cholanians, Aram B.; Lau, Serrine S.; Monks, Terrence J. (March 2014). “Glial Cell Response to 3,4-(±)-Methylenedioxymethamphetamine and Its Metabolites”. Toxicological Sciences 138 (1): 130-138. doi:10.1093/toxsci/kft275. ISSN 1096-6080. PMC 3930364. PMID 24299738.
Kalant, Harold (2001-10-02). “The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs”. CMAJ: Canadian Medical Association Journal 165 (7): 917-928. ISSN 0820-3946. PMC 81503. PMID 11599334.
“Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class”. Bioorg. Med. Chem. 19 (23): 7044-8. (December 2011). doi:10.1016/j.bmc.2011.10.007. PMC 3236098. PMID 22037049.
“Therapeutic potential of monoamine transporter substrates”. Curr Top Med Chem 6 (17): 1845-59. (2006). doi:10.2174/156802606778249766. PMID 17017961.
Rothman, Richard B; Baumann, Michael H (2009). “Serotonergic drugs and valvular heart disease”. Expert Opinion on Drug Safety 8 (3): 317-329. doi:10.1517/14740330902931524. ISSN 1474-0338. PMC 2695569. PMID 19505264.
“Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors”. Neurosci. Lett. 177 (1-2): 111-5. (1994). doi:10.1016/0304-3940(94)90057-4. PMID 7824160.
Manzoni, Olivier Jacques; Ray, Thomas S. (2010). “Psychedelics and the Human Receptorome”. PLoS ONE 5 (2): e9019. doi:10.1371/journal.pone.0009019. ISSN 1932-6203. PMC 2814854. PMID 20126400.
Muszynski, I.E. (1961). “Production of some amphetamine derivatives”. Acta Poloniae Pharmaceutica 18: 471-478. PMID 14477621.
Noggle, FT Jr; DeRuiter, J.; Long, MJ. (1986). “Spectrophotometric and liquid chromatographic identification of 3,4-methylenedioxyphenylisopropylamine and its N-methyl and N-ethyl homologs”. Journal Association of Official Analytical Chemists 69 (4): 681-686. PMID 2875058.
Ho, Beng-Thong; McIsaac, William M.; An, Rong; Tansey, L. Wayne; Walker, Kenneth E.; Englert Jr., Leo F.; Noel, Michael B. (1970). “Analogs of a-methylphenethylamine”. Journal of Medicinal Chemistry 13 (1): 26-30. doi:10.1021/jm00295a007. PMID 5412110.
“Disposition of MDMA and metabolites in human sweat following controlled MDMA administration”. Clinical Chemistry 55 (3): 454-62. (2009). doi:10.1373/clinchem.2008.117093. PMC 2669283. PMID 19168553.
Yensen, R.; Di Leo, F. B.; Rhead, J. C.; Richards, W. A.; Soskin, R. A.; Turek, B.; Kurland, A. A. (1976). “MDA-assisted psychotherapy with neurotic outpatients: a pilot study”. The Journal of Nervous and Mental Disease 163 (4): 233-245. doi:10.1097/00005053-197610000-00002. PMID 972325.
“Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers”. Journal of Psychoactive Drugs 51 (2): 108–117. (2019-03-15). doi:10.1080/02791072.2019.1593560. PMID 30967099.

pmc.ncbi.nlm.nih.gov

Crean, R. D.; Davis, S. A.; Von Huben, S. N.; Lay, C. C.; Katner, S. N.; Taffe, M. A. (2006-10-13). “Effects of (±)3,4-methylenedioxymethamphetamine, (±)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques”. Neuroscience 142 (2): 515-525. doi:10.1016/j.neuroscience.2006.06.033. PMC 1853374. PMID 16876329.
Baggott, MJ; Siegrist, JD; Galloway, GP; Robertson, LC; Coyle, JR; Mendelson, JE (2010). “Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxeamphetamine (MDA): A Randomized Controlled Trial in Humans”. PLOS ONE 5 (12): e14074. doi:10.1371/journal.pone.0014074. PMC 2996283. PMID 21152030.
Herndon, Joseph M.; Cholanians, Aram B.; Lau, Serrine S.; Monks, Terrence J. (March 2014). “Glial Cell Response to 3,4-(±)-Methylenedioxymethamphetamine and Its Metabolites”. Toxicological Sciences 138 (1): 130-138. doi:10.1093/toxsci/kft275. ISSN 1096-6080. PMC 3930364. PMID 24299738.
Kalant, Harold (2001-10-02). “The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs”. CMAJ: Canadian Medical Association Journal 165 (7): 917-928. ISSN 0820-3946. PMC 81503. PMID 11599334.
“Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class”. Bioorg. Med. Chem. 19 (23): 7044-8. (December 2011). doi:10.1016/j.bmc.2011.10.007. PMC 3236098. PMID 22037049.
Rothman, Richard B; Baumann, Michael H (2009). “Serotonergic drugs and valvular heart disease”. Expert Opinion on Drug Safety 8 (3): 317-329. doi:10.1517/14740330902931524. ISSN 1474-0338. PMC 2695569. PMID 19505264.
Manzoni, Olivier Jacques; Ray, Thomas S. (2010). “Psychedelics and the Human Receptorome”. PLoS ONE 5 (2): e9019. doi:10.1371/journal.pone.0009019. ISSN 1932-6203. PMC 2814854. PMID 20126400.
“Disposition of MDMA and metabolites in human sweat following controlled MDMA administration”. Clinical Chemistry 55 (3): 454-62. (2009). doi:10.1373/clinchem.2008.117093. PMC 2669283. PMID 19168553.

ncbi.nlm.nih.gov

Crean, R. D.; Davis, S. A.; Von Huben, S. N.; Lay, C. C.; Katner, S. N.; Taffe, M. A. (2006-10-13). “Effects of (±)3,4-methylenedioxymethamphetamine, (±)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques”. Neuroscience 142 (2): 515-525. doi:10.1016/j.neuroscience.2006.06.033. PMC 1853374. PMID 16876329.
Baggott, MJ; Siegrist, JD; Galloway, GP; Robertson, LC; Coyle, JR; Mendelson, JE (2010). “Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxeamphetamine (MDA): A Randomized Controlled Trial in Humans”. PLOS ONE 5 (12): e14074. doi:10.1371/journal.pone.0014074. PMC 2996283. PMID 21152030.
Herndon, Joseph M.; Cholanians, Aram B.; Lau, Serrine S.; Monks, Terrence J. (March 2014). “Glial Cell Response to 3,4-(±)-Methylenedioxymethamphetamine and Its Metabolites”. Toxicological Sciences 138 (1): 130-138. doi:10.1093/toxsci/kft275. ISSN 1096-6080. PMC 3930364. PMID 24299738.
Kalant, Harold (2001-10-02). “The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs”. CMAJ: Canadian Medical Association Journal 165 (7): 917-928. ISSN 0820-3946. PMC 81503. PMID 11599334.
“Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class”. Bioorg. Med. Chem. 19 (23): 7044-8. (December 2011). doi:10.1016/j.bmc.2011.10.007. PMC 3236098. PMID 22037049.
Rothman, Richard B; Baumann, Michael H (2009). “Serotonergic drugs and valvular heart disease”. Expert Opinion on Drug Safety 8 (3): 317-329. doi:10.1517/14740330902931524. ISSN 1474-0338. PMC 2695569. PMID 19505264.
Manzoni, Olivier Jacques; Ray, Thomas S. (2010). “Psychedelics and the Human Receptorome”. PLoS ONE 5 (2): e9019. doi:10.1371/journal.pone.0009019. ISSN 1932-6203. PMC 2814854. PMID 20126400.

psychedelicresearch.org

“The First MDA trip and the measurement of 'mystical experience' after MDA, LSD, and Psilocybin”. Psychedelic research (July 18, 2008). July 13, 2012時点のオリジナルよりアーカイブ。2020年12月7日閲覧。

worldcat.org

search.worldcat.org

Herndon, Joseph M.; Cholanians, Aram B.; Lau, Serrine S.; Monks, Terrence J. (March 2014). “Glial Cell Response to 3,4-(±)-Methylenedioxymethamphetamine and Its Metabolites”. Toxicological Sciences 138 (1): 130-138. doi:10.1093/toxsci/kft275. ISSN 1096-6080. PMC 3930364. PMID 24299738.
Kalant, Harold (2001-10-02). “The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs”. CMAJ: Canadian Medical Association Journal 165 (7): 917-928. ISSN 0820-3946. PMC 81503. PMID 11599334.
Rothman, Richard B; Baumann, Michael H (2009). “Serotonergic drugs and valvular heart disease”. Expert Opinion on Drug Safety 8 (3): 317-329. doi:10.1517/14740330902931524. ISSN 1474-0338. PMC 2695569. PMID 19505264.
Manzoni, Olivier Jacques; Ray, Thomas S. (2010). “Psychedelics and the Human Receptorome”. PLoS ONE 5 (2): e9019. doi:10.1371/journal.pone.0009019. ISSN 1932-6203. PMC 2814854. PMID 20126400.
Elks, J.; Hey, D. H. (1943). “7. β-3 : 4-Methylenedioxyphenylisopropylamine”. J. Chem. Soc. 0: 15-16. doi:10.1039/JR9430000015. ISSN 0368-1769.

youtube.com

The History Channel documented details of his death here https://www.youtube.com/watch?v=ySw-0uY4CUA See minute 2:38 onward.

zenodo.org

“Therapeutic potential of monoamine transporter substrates”. Curr Top Med Chem 6 (17): 1845-59. (2006). doi:10.2174/156802606778249766. PMID 17017961.
Mannich, C.; Jacobsohn, W.; Mannich, Hr. C. (1910). “Uber Oxyphenyl-alkylamine und Dioxyphenyl-alkylamine”. Berichte der Deutschen Chemischen Gesellschaft 41 (1): 189-197. doi:10.1002/cber.19100430126. https://zenodo.org/record/1426387.